about
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A ReviewDevelopment and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approachDoes safety make a difference in selecting the right TNF antagonist?Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor.The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitorsIncidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).Does route of administration affect the outcome of TNF antagonist therapy?Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept.Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy.Protein therapeutics--lessons learned and a view of the future.Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe diseaseClinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Engineering the variable region of therapeutic IgG antibodies.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.Clinical safety of biosimilar recombinant human erythropoietins.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical development of biosimilars: an evolving landscape.Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers.Biosimilar therapeutics-what do we need to consider?Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies.Biosimilars in 3D: definition, development and differentiationAggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.Development of a new G-CSF product based on biosimilarity assessment.The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309.Characterization of anti-natalizumab antibodies in multiple sclerosis patients.Is it congenital or acquired von Willebrands disease?High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.Immunogenicity issues in drug development.Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.A safety evaluation of evolocumab.Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial.Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
P2860
Q26799856-EED3C3EE-0E6E-4057-9B2E-015DD92353B8Q26865481-44406CEC-D5CE-4009-B78A-E51B38038BFCQ33708863-865864A8-104A-4197-91C9-55D2A688F3CCQ34207914-80A378AB-2453-4FAD-B26D-363D8D9BB2B0Q34629805-C7D1883C-C4B8-4E85-87AB-0D0B6F8CE5EBQ34964772-8F5C5E67-0529-4E90-87EA-B3DD386E9EF2Q35119023-02D9AB2C-F1E8-431A-AD52-9C0657B49E40Q35823645-7F2E91A6-19CC-427B-B78F-94AAE336A884Q36194054-5A86E3EB-079D-4B11-AEF6-4FA56F2C246CQ36216186-79F9388B-074E-4806-AD98-7CB2A1DD069CQ36349537-6070DF2D-63E0-445D-9D96-59CD5B295A87Q37097386-AC1D2E56-22D0-4DEA-BAEF-627A5BB69C8AQ37700537-E5FD9FEC-3011-4626-82C9-69EB37B51292Q37853324-EC548B9E-0576-474E-86FB-05D808BF74B6Q37950838-FB9AFACD-CD90-4A2C-9D61-3F68AB2F1EE2Q37999380-84D805FE-8CD4-43C0-984F-2C68FF364D7DQ37999739-9F9D907D-FCEA-4631-BBC3-3E4C8B126F51Q38033576-E11114C2-386A-42FE-996D-63B923A5614AQ38082542-72453B72-C58F-4714-9662-67CDF2B67BC1Q38083094-240940EC-E5F6-4AB3-8781-E7451E8577EAQ38621461-70A1DA88-4A39-4FA5-B8F5-BE19B91E4CB7Q38643965-5AA2EB15-CD59-4DF5-A189-93B5DDF92B72Q40890012-2A5B9A22-1476-474F-A476-4C4ED9DC8649Q41841849-BB7BB369-8EF4-48C7-96C3-05891D6A3CE1Q41954237-19550168-94A7-4269-850C-8EEE057AA763Q41961612-7375FFBF-F20B-4C1E-9272-9D6324DFEF28Q42578789-E729D4BD-D85C-425A-91B7-1016F4CB0371Q42643304-B067E137-321A-4C56-9C90-A189A762A8E5Q43952080-8347CC94-1241-4796-BEAB-B303FE0A193DQ44171101-58BED0D0-C346-49D7-979A-823D675E98BDQ45870015-97D58C5D-E469-4F8D-AD6C-586E0E5538EBQ45998750-71C41211-B0DF-4DF5-A264-B31D68237D83Q46717338-14D6C284-B96E-4CC0-A25C-76D42CE278F7Q46728001-9814BC4E-8DA0-4022-A90A-32FBA91AFFFDQ47681415-155CB081-CDF5-4154-9869-9F6B9441BD26Q48903472-EE698BD1-3273-499D-A9FF-71B4693445BCQ50533140-DDA364BC-3AFC-48A4-8A56-6B5B19655B2DQ50654749-5B57D2E1-530C-4556-95AF-9C2E1A5A7795
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Human immune response to recombinant human proteins.
@ast
Human immune response to recombinant human proteins.
@en
Human immune response to recombinant human proteins.
@nl
type
label
Human immune response to recombinant human proteins.
@ast
Human immune response to recombinant human proteins.
@en
Human immune response to recombinant human proteins.
@nl
prefLabel
Human immune response to recombinant human proteins.
@ast
Human immune response to recombinant human proteins.
@en
Human immune response to recombinant human proteins.
@nl
P1476
Human immune response to recombinant human proteins.
@en
P2093
P356
10.1002/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K
P407
P577
2001-01-01T00:00:00Z